Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab

Phase 2/3 Terminated 20 enrolled University of California, San Diego Genentech, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

To determine if patients treated early after diagnosis of wet age-related macular degeneration can return/maintain to their baseline pre-disease BCVA.

Timeline

Start: 2011-07
Primary completion: 2015-03
Completion: 2015-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ranibizumab	Monoclonal antibody	0.5 mg	Intravitreal

Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab

Summary

Timeline

Drugs

Indications